OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody.

ABSTRACT:

Background

Anti-PD-1 monoclonal antibody, nivolumab, has shown efficacy for advanced gastric cancer (AGC). However, the specific immune cell subsets predominantly activated during the period of anti-PD-1 therapy for AGC have not been clarified.

Methods

Peripheral blood of 30 AGC patients treated with nivolumab was prospectively obtained before the initial and second administrations and at the time of progressive disease (PD). The proportions of immune cell subsets and the serum concentrations of cytokines were systematically analysed by flow cytometry. Associations of subsets and serum cytokines with therapeutic effects were evaluated.

Results

After the initial administration, significant increases in activated central/effector memory, activated effector T cells, and

SUBMITTER: Ohmura H 

PROVIDER: S-EPMC7217874 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature